Abstract
Alpha-galactosidase A, the enzyme deficient in Fabry disease, is a polypeptide of 429 amino acids encoded by the seven exons of the GLA gene. From the literature, a total of 599 GLA sequence changes, including 435 pathogenic point mutations (missense, nonsense, and splice site) and 150 disease causing ‘short length’ rearrangements (mainly deletions and duplications affecting less than 65 nucleotides) as well as 14 DNA polymorphisms were compiled. While no obvious mutation ‘hot spots’ for point mutations were detected, about 30% of the rearrangements occurred in exon 7, which accounts for only 22.6% of the coding region. The clinical phenotype in Fabry disease can be extremely variable, both in males and females, within the same family and among patients from unrelated families carrying the same mutation. Thus establishing genotype–phenotype correlations in Fabry disease is not straight forward and usually requires the analysis of large cohorts of probands. In addition to patients with the classic Fabry disease phenotype, a considerable number of patients have been described that presented with an ‘oligosymptomatic’ phenotype, occasionally called cardiac or renal forms. This attenuated phenotype is characterized by later onset and slower progression of the disease, the patients are older at the time of major organ failure, and show a longer survival. Results of the few studies reported to date suggest that the attenuated phenotype is more often seen in patients with missense mutations than in those carrying constitutional or functional null alleles. Thirty-three different missense mutations have been reported to date in patients with attenuated phenotypes. The great majority of the residues affected by these mutations seem to be partially, mostly, or completely buried in the 3D-crystallographic structure model of α-galactosidase A. About half of the variants represent conservative amino acid changes, and only about 25% of the residues are considered evolutionarily highly conserved. While during the past years some progress has been made in the analysis of the correlation between GLA mutations and the patients’ phenotypes, there are only very few data on the phenotypic effect of other genes (so called modifiers) in patients with Fabry disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Eng CM, Niehaus DJ, Enriquez AL et al (1994) Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the α-galactosidase A gene. Hum Mol Genet 3(10):1795–1799
Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (2000) Fabry disease: twenty-two novel mutations in the α-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Invest Med 48(4):227–235
Shabbeer J, Yasuda M, Luca E, Desnick RJ (2002) Fabry disease: 45 novel mutations in the α-galactosidase A gene causing the classical phenotype. Mol Genet Metab 76:23–30
Gal A, Schäfer E, Rohard I (2006) The genetic basis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford, pp 323–330
Shabbeer J, Yasuda M, Benson SD, Desnick RJ (2006) Fabry disease: identification of 50 novel α-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics 2(5):297–309
Eng CM, Ashley GA, Burgert TS, Enriquez AL, D’Souza M, Desnick RJ (1997) Fabry disease: thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3(3):174–182
Lai LW, Whitehair O, Wu M-J, O’Meara M, Lien Y-H H (2003) Analysis of splice-site mutations of the α-galactosidase A gene in Fabry disease. Clin Genet 63:476–482
Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ (2002) Alternative splicing in the α-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 70:994–1002
Filoni C, Caciotti A, Carraresi L et al (2008) Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients’ fibroblasts results in Fabry disease. Eur J Hum Genet 16(11):1311–1317
Schäfer E, Baron K, Widmer U et al (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25(4):412
Dobyns WB (2006) The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. Acta Paediatr 95(Suppl 451):11–15
Brouns R, Eyskens F, de Boeck K et al (2009) Fabry disease in a patient with Turner syndrome. J Inherit Metab Dis. Short report #162. doi 10.1007/s10545-009-1035–x
Rodríguez-Marí A, Coll MJ, Chabás A (2003) Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 22(3):258
Ries M, Gal A (2006) Genotype–phenotype correlation in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford, pp 331–336
Matsuzawa F, Akikawa S, Doi H, Okumiya T, Sakuraba H (2005) Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes. Hum Genet 117(4):317–328
Altarescu GM, Goldfarb LG, Park K-Y et al (2001) Identification of fifteen novel mutations and genotype – phenotype relationship in Fabry disease. Clin Genet 60:46–51
Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry disease. Influence of α-galactosidase A activity and genetic mutations on clinical course. Medicine 81(2):122–138
Schäfer E, Mehta A, Gal A (2005) Genotype and phenotype in Fabry disease: analysis of the Fabry outcome survey. Acta Paediatr 94(Suppl 447):87–92
Henikoff JG, Henikoff S (1996) Blocks database and its applications. Methods Enzymol 266:88–105
Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human α-galactosidase. J Mol Biol 337:319–335
Garman SC (2007) Structure-function relationships in α-galactosidase A. Acta Paediatr 96(Suppl 455):6–16
Germain DP, Shabbeer J, Cotigny S, Desnick RJ (2002) Fabry disease: twenty novel α-galactosidase A mutations and genotype–phenotype correlations in classical and variant phenotypes. Mol Med 8(6):306–312
Davies JP, Winchester BG, Malcolm S (1993) Mutation analysis in patients with the typical form of Anderson – Fabry disease. Hum Mol Genet 2(7):1051–1053
Rohard I, Schaefer E, Kampmann C, Beck M, Gal A (2008) Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease. J Inherit Metab Dis. Short report #122. doi 10.1007/s10545-008-0920–z
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Netherlands
About this chapter
Cite this chapter
Gal, A. (2010). Molecular Genetics of Fabry Disease and Genotype–Phenotype Correlation. In: Elstein, D., Altarescu, G., Beck, M. (eds) Fabry Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9033-1_1
Download citation
DOI: https://doi.org/10.1007/978-90-481-9033-1_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9032-4
Online ISBN: 978-90-481-9033-1
eBook Packages: MedicineMedicine (R0)